Literature DB >> 7010165

The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients.

M L Tuck, J Sowers, L Dornfeld, G Kledzik, M Maxwell.   

Abstract

We investigated the relation between changes in the renin-aldosterone axis and reduction in blood pressure in 25 obese patients placed on a 12-week reducing diet; sodium intake was either medium (120 mmol) or low (40 mmol). Plasma renin activity (PRA) declined with weight loss, so that by 12 weeks there was a significant decrease in PRA (P less than 0.01) as well as plasma aldosterone (P less than 0.05), regardless of sodium intake. Weight loss with low sodium intake was equal to that with medium intake. The reduction in PRA but not in aldosterone correlated with weight loss in both sodium-intake groups (r = 0.58). Mean arterial pressure fell significantly and equally in both groups, correlating with weight loss throughout the study (r = 0.56) and with PRA from the fourth through 12th weeks (r = 0.48) These results demonstrate that weight loss is accompanied by reductions in PRA and aldosterone; PRA reductions, irrespective of sodium intake, may contribute to the decline in blood pressure.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7010165     DOI: 10.1056/NEJM198104163041602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  117 in total

Review 1.  Obesity and hypertension.

Authors:  E Faloia; G Giacchetti; F Mantero
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

Review 2.  The medical risks of obesity.

Authors:  F Xavier Pi-Sunyer
Journal:  Obes Surg       Date:  2002-04       Impact factor: 4.129

Review 3.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

4.  Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets.

Authors:  J M Luther; P Luo; M T Kreger; M Brissova; C Dai; T T Whitfield; H S Kim; D H Wasserman; A C Powers; N J Brown
Journal:  Diabetologia       Date:  2011-04-26       Impact factor: 10.122

Review 5.  Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: rationale and options.

Authors:  Guido Grassi
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 6.  Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications.

Authors:  Graziela Z Kalil; William G Haynes
Journal:  Hypertens Res       Date:  2011-11-03       Impact factor: 3.872

7.  A rare cardiac finding in a morbidly obese patient with severe hypertension.

Authors:  Anna Maria Vittoria Fiore; Giorgia Michela Marinoni; Alessandro Piccione; Maria Adelaide Marini; Monica D'Adamo; Renato Lauro; Paolo Sbraccia
Journal:  Intern Emerg Med       Date:  2010-10-09       Impact factor: 3.397

Review 8.  Obesity and cardiovascular disease in women.

Authors:  Camila Manrique-Acevedo; Bhavana Chinnakotla; Jaume Padilla; Luis A Martinez-Lemus; David Gozal
Journal:  Int J Obes (Lond)       Date:  2020-02-17       Impact factor: 5.095

9.  Mineralocorticoid receptor antagonism prevents obesity-induced cerebral artery remodeling and reduces white matter injury in rats.

Authors:  Paulo W Pires; Jonathon L McClain; Sebastian F Hayoz; Anne M Dorrance
Journal:  Microcirculation       Date:  2018-06-07       Impact factor: 2.628

Review 10.  Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.

Authors:  Badhma Valaiyapathi; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.